Characterization of BIS20x3, a bi-specific antibody activating and retargeting T-cells to CD20-positive B-cells
2001
BIS20x3: A New Antibody for Targeting B-Cells
publication
Evidence: moderate
Author Information
Author(s): Withoff S, Bijman M N A, Stel A J, Delahaye L, Calogero A, Jonge M W A de, Kroesen B J, Leij L de
Primary Institution: Department of Pathology and Laboratory Medicine, University Hospital Groningen
Hypothesis
BIS20x3 can effectively retarget T-cells to CD20-positive B-cells.
Conclusion
BIS20x3 is functional in retargeting T-cells to B-cells and may be effective in treating B-cell lymphomas.
Supporting Evidence
- BIS20x3 can retarget T-cells to B-cells effectively.
- The antibody retains signaling characteristics of both chains.
- T-cell activation occurs upon cross-linking with BIS20x3.
Takeaway
Scientists created a special antibody that helps T-cells find and attack bad B-cells, which could help treat certain blood cancers.
Methodology
The antibody was obtained through hybrid–hybridoma fusion and tested for its ability to activate T-cells and target B-cells.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website